2022
DOI: 10.1016/j.blre.2021.100912
|View full text |Cite
|
Sign up to set email alerts
|

Clinical burden of hemophilia in older adults: Beyond bleeding risk

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(9 citation statements)
references
References 99 publications
0
9
0
Order By: Relevance
“…Haemophilia A (HA) and Haemophilia B (HB) are the most common severe bleeding disorders in humans, and are caused by inherited X‐linked mutations in the genes encoding coagulation factor VIII (FVIII) in the case of HA and factor IX (FIX) in the case of HB (Hodroj et al., 2021 ). Recent reports on the worldwide distribution indicate the prevalence of HA and HB to be 17.1 and 3.8 cases per 100,000 males, respectively (Mannucci, 2020b ).…”
Section: Resultsmentioning
confidence: 99%
“…Haemophilia A (HA) and Haemophilia B (HB) are the most common severe bleeding disorders in humans, and are caused by inherited X‐linked mutations in the genes encoding coagulation factor VIII (FVIII) in the case of HA and factor IX (FIX) in the case of HB (Hodroj et al., 2021 ). Recent reports on the worldwide distribution indicate the prevalence of HA and HB to be 17.1 and 3.8 cases per 100,000 males, respectively (Mannucci, 2020b ).…”
Section: Resultsmentioning
confidence: 99%
“…There are long-term clinical concerns associated with hemophilia outcomes, including chronic viral infections with liver disease, joint impairment with bone disease, cardiovascular disease, cancers, chronic kidney disease, covert cerebral microbleeds, impaired sexuality and development of immune factor inhibitors. 18 …”
Section: Present Health Care Status Of Females With Inherited Bleedin...mentioning
confidence: 99%
“…The current global prevalence of haemophilia A and B is close to 17.1 and 3.8 cases per 100,000 males, respectively 4 . From the early 1970s, with the manufacture of specific plasma‐derived factor concentrates and the use of recombinant DNA technology, the mortality rate in haemophilia was significantly reduced 5 . Over the past decade, life expectancy for PWH has increased from 20 years in the 11th century to 55−63 years after the introduction of factor concentrates and more than 65 years in recent reports from the Netherlands and Italy 5 …”
Section: Introductionmentioning
confidence: 99%